Cargando…

Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Guha, Avirup, Sayegh, Nicolas, Agarwal, Neeraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270611/ https://www.ncbi.nlm.nih.gov/pubmed/35818554 http://dx.doi.org/10.1016/j.jaccao.2022.05.007

Ejemplares similares

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies
por: Chen, Dong-Yi, et al.
Publicado: (2022)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
por: Fradley, Michael G., et al.
Publicado: (2023)

Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
por: Lee, Jee Han, et al.
Publicado: (2010)

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma
por: Stenehjem, David D., et al.
Publicado: (2019)

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
por: Dent, Susan F., et al.
Publicado: (2021)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials
por: Prasad, Rahul N., et al.
Publicado: (2021)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

Immuno-oncology therapy associated thromboembolic events in metastatic renal cell carcinoma
por: Alhamdani, Zein, et al.
Publicado: (2023)

Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
por: Wong, Emily C.L., et al.
Publicado: (2019)

Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma
por: Sayegh, Nicolas, et al.
Publicado: (2022)

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
por: Leucht, Katharina, et al.
Publicado: (2022)

CAR T Cell Therapy–Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?
por: Ghosh, Arjun K., et al.
Publicado: (2020)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
por: Guha, Avirup, et al.
Publicado: (2021)

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
por: Miyauchi, Yasuyuki, et al.
Publicado: (2021)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
por: Chitturi, Kalyan R., et al.
Publicado: (2019)

A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Mihály, Z, et al.
Publicado: (2012)

Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
por: Wang, Lisha, et al.
Publicado: (2014)

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Feng, Yao-Ning, et al.
Publicado: (2023)

Metastatic Merkel Cell Carcinoma Masquerading as Multiple Immune-Related Adverse Events
por: Saqlain, Farees, et al.
Publicado: (2020)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Percutaneous resection of metastatic renal cell carcinoma
por: Toussi, Amir, et al.
Publicado: (2019)

Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy
por: Song, Yan, et al.
Publicado: (2016)

Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
por: Kim, Sung Han, et al.
Publicado: (2016)

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
por: Chrom, Pawel, et al.
Publicado: (2018)

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
por: Pal, Sumanta, et al.
Publicado: (2019)

A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma
por: Singh, Vinit, et al.
Publicado: (2020)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Paderi, Agnese, et al.
Publicado: (2021)

Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
por: Kobayashi, Mizuki, et al.
Publicado: (2022)

Blepharoptosis revealing a metastatic renal cell carcinoma: A rare case report
por: Bellouki, Omar, et al.
Publicado: (2023)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

Sequential Therapy in Metastatic Renal Cell Carcinoma
por: Hirsch, Bradford R., et al.
Publicado: (2016)

An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases
por: Semenescu, Liliana Eleonora, et al.
Publicado: (2023)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ged6aot8iv02ccirna0pfu8b7i